SCHEMBL2126196

SCHEMBL2126196

Cc1c(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)nc2cccc(F)c2c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.47
TOP1 P11387 1/20 0.36
PARP1 P09874 2/20 0.36
DHODH Q02127 4/20 0.36
KDM4E B2RXH2 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C9 P11712 2/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34
CYP2C19 P33261 1/20 0.34
NLRP3 Q96P20 1/20 0.34
RORB Q92753 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
THRB P10828 1/20 0.34
PKM P14618 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2608549 0.94 PIK3CA (0.43) PIK3CATOP1PARP1DHODHKDM4E
SCHEMBL2712817 0.77 CYP11B1 (0.40) PIK3CAPARP1DHODHCYP3A4RORC
SCHEMBL2125770 0.76 DHODH (0.38) PARP1DHODHMBNL1
SCHEMBL2124656 0.75 PIK3CA (0.46) PIK3CADHODHKDM4ECYP1A2CYP3A4
SCHEMBL2126972 0.75 CYP11B2 (0.43) DHODHKDM4ECYP3A4RORC
SCHEMBL2124507 0.75 MBNL1 (0.51) PIK3CAPARP1DHODHNPC1ALDH1A1
SCHEMBL2126781 0.73 PARP1 (0.46) PARP1TNKSTNKS2L3MBTL1
SCHEMBL2126492 0.72 CCR1 (0.40) PIK3CAPARP1MBNL1
SCHEMBL244335 0.71 NPC1 (0.48) PIK3CAPARP1KDM4EHTTSMN1; SMN2
SCHEMBL2608548 0.70 PIK3CA (0.42) PIK3CADHODHKDM4ECYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 US disclosed
US-8765940-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2014-07-01 US disclosed
EP-2445902-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY Amgen, Inc (US) 2012-05-02 EP disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 US disclosed
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-04-19 US disclosed
WO-2010151737-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed
WO-2010151737-A2 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094972-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 PIK3CA 28/4885TOP1 713/4885PARP1 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.